Novartis (0QLR, NVS) → Stock, financial statements
Advertising

Novartis: stocks, financial statements

Dividends News
Favorites

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

  • 0QLR, NVS Ticker
  • 🇬🇧 LSE, 🇺🇸 NYSE Exchange
  • 125,161 Employees
16 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements — Novartis

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
20 ← 16 2020 2019 2018 2017 2016
Total Revenue
50B 49B 53B 50B 49B
Cost Of Revenue
15B 14B 18B 17B 18B
Gross Profit
35B 34B 35B 33B 32B
Research and Development
9B 9.4B 9.1B 9B 9B
Selling General and Admin
14B 14B 16B 15B 14B
Operating Expense
38B 38B 44B 41B 41B
Operating Income
12B 10B 9.2B 9B 8.7B
Other Income Expense Net
0 0 0 0 0
EBIT
12B 11B 16B 10B 9.4B
Interest Income
780M 850M 600M 670M 660M
Pretax Income
9.9B 8.9B 14B 9B 7.8B
Income Tax
1.8B 1.8B 1.2B 1.3B 1.1B
Minority Interest
-1M 5M 3M 0 -14M
Net Income
8.1B 12B 13B 7.7B 6.7B
Net Income Basic
8.1B 12B 13B 7.7B 6.7B
20 ← 16 2020 2019 2018 2017 2016
Current cash
12B 11B 16B 9.5B 7.8B
Short term investments
1.9B 2.1B 2.2B 1.8B 1.7B
Receivables
9.1B 9.2B 9.7B 10B 9.2B
Inventory
7.1B 6B 7B 6.9B 6.3B
Other current assets
1.9B 2.1B 2.2B 1.8B 1.7B
Current assets
30B 30B 36B 28B 25B
Long term investments
100B 89B 110B 100B 110B
Property plant equipment
12B 12B 16B 16B 16B
Goodwill
30B 27B 35B 32B 31B
Intangible assets
37B 29B 39B 30B 31B
Other assets
3B 2.7B 1.3B 1.3B 1.3B
Total assets
130B 120B 150B 130B 130B
Accounts payable
5.4B 5.4B 5.6B 5.2B 4.9B
Current long term debt
9.9B 7.1B 9.6B 5.2B 5.8B
Other current liabilities
18B 16B 14B 13B 12B
Total current liabilities
33B 28B 30B 23B 22B
Long term debt
28B 22B 22B 23B 18B
Other liabilities
6.9B 6.6B 7.3B 7.1B 8.5B
Minority Interest
68M 77M 78M 59M 59M
Total Liabilities
75B 63B 67B 59B 55B
Common stock
2.3B 2.3B 2.3B 2.3B 2.4B
Retained earning
0 0 0 0 0
Treasury stock
-53M -80M -69M -100M -76M
Capital surplus
Shareholder equity
57B 55B 79B 74B 75B
Net tangible assets
-10B 160M 4.6B 12B 13B
20 ← 16 2020 2019 2018 2017 2016
Net Income
8.1B 12B 13B 7.7B 6.7B
Depreciation
6.5B 5.8B 6.9B 6.1B 6B
Changes in receivables
-99M -490M -410M 900M -1.4B
Changes in inventories
1.1B -970M 89M 610M 29M
Cash change
120M -4.5B 6.5B 1.7B 2.3B
Cash flow
14B 14B 14B 13B 11B
Capital expenditures
-2.6B -1.4B -3.4B -2.8B -3.1B
Investments
Investing activity other
Total investing cash flows
-13B -2.2B -5.6B -3.1B -3.4B
Dividends paid
Net borrowings
24B 16B 14B 17B 14B
Other financing cash flows
Cash flow financing
-2.2B -14B -4.2B -7.7B -5.3B
Exchange rate effect